Publication Highlight: Developing a Shared Nomenclature for Radiopharmaceutical Therapy

As the field of radiopharmaceutical therapy continues to evolve, the need for clear and consistent terminology is becoming increasingly important.

In the publication, “The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond,” leading oncology and nuclear medicine experts discuss how the FDA’s 505(b)(2) approval pathway is shaping the radioligand therapy landscape and why a shared nomenclature will be essential as the field expands.

Authored by Aman Chauhan, Andrew E. Hendifar, Ghassan El-Haddad, Heloisa P. Soares and Ken Herrmann, the article explores the importance of precise terminology to support scientific communication, clinical practice and stakeholder understanding across the radiopharmaceutical therapy ecosystem.

As innovation continues to advance, establishing a common language can help improve clarity and alignment among healthcare professionals, researchers, regulators and industry stakeholders.

Read the full publication: https://jnm.snmjournals.org/content/early/2026/04/30/jnumed.126.272026